Stroke drug tirofiban may boost recovery after clot removal

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years old; 2. NIHSS score: 6-30; 3. Symptom onset to random time of 24h, including wake-up stroke or unwitnessed stroke; The onset time of symptoms was defined as the last time of normal performance. 4. mRS 0-1 before the stroke; 5. Subject or legal representative can sign an informed consent form; 6. Clinical symptoms caused by acute occlusion of the following sites confirmed by CTA or MRA: intracranial segment of ICA, M1 segment of middle cerebral artery, M2 trunk of middle cerebral artery; 7. ASPECTS≥6 on NCCT or DWI; 8. After the end of mechanical thrombectomy, the mTICI was stable at 2b/3, and there was no secondary embolism in other non-offending vessels, or the diagnostic angiography before mechanical thrombectomy showed that the occluded vessels improved to mTICI 2b/3, and no mechanical thrombectomy was planned. Exclusion Criteria: 1. Intra-arterial thrombolysis; 2. Tirofiban was used within 24 hours before endovascular treatment 3. Women who are known to be pregnant or lactating, or have a positive pregnancy test before randomization; 4. Allergy to tirofiban, radiocontrast agent or Nitinol materials; 5. Any active bleeding within 30 days before stroke or recent bleeding (gastrointestinal, urinary, etc.); 6. parenchymal organ surgery or biopsy within 14 days before stroke; 7. History of heparin-induced thrombocytopenia; 8. Platelet count \< 100\*10\^9/L; 9. Being on hemodialysis or peritoneal dialysis; Known severe renal insufficiency (glomerular filtration rate \&lt; 30ml/min or serum creatinine \&gt; 220μmol/L). 10. Subjects requiring hemodialysis or peritoneal dialysis or who have contraindications to angiography for any reason; 11. The expected survival time is less than half a year (such as malignant tumors, serious heart and lung diseases, etc.); 12. Have participated in other interventional clinical studies that may have an impact on the outcome assessment; 13. Other circumstances that the investigator considers inappropriate for participation in the study or that may pose a significant risk to the patient (e.g., inability to understand and/or comply with study procedures and/or follow-up due to mental illness, cognitive or emotional disorder). 14. The midline shift of the brain or cerebral hernia, ventricular mass effect; 15. Acute intracranial hemorrhage on CT or MRI; 16. New bilateral acute stroke or intracranial multi-drainage large vessel occlusion; 17. Simple extracranial occlusion of the internal carotid artery.